HCV Program (BEM/RZR) - The company is developing BEM/RZR as a potential best-in-class treatment for HCV, with Phase 3 trials underway[7, 12] - Phase 2 results showed a 98% sustained virologic response (SVR12) with the BEM/RZR combination regimen[12] - Two Phase 3 trials, C-BEYOND (US/Canada) and C-FORWARD (outside North America), are enrolling approximately 1,760 patients in total[12, 30] - The US sees over 160 thousand new chronic HCV infections annually, while approximately 90 thousand are treated, highlighting the need for improved treatment strategies[18] - Market research indicates that 48% of non-cirrhotic patients and 49% of compensated cirrhotic patients are likely to be prescribed BEM/RZR[21] HEV Program (AT-587) - A new program is focused on Hepatitis E Virus (HEV) with product candidate AT-587, targeting Phase 1 initiation in mid-2026[7] - The WHO estimates up to 20 million global HEV infections annually[42] - Approximately 3% of at-risk patients develop chronic HEV, leading to a potential treatment population of ~135 thousand patients annually[51] - The commercial opportunity for HEV treatment in the US & EU is estimated at $750 million to $1 billion[50, 51] - AT-587 demonstrates potent antiviral activity against multiple HEV-3 strains and ribavirin-resistant virus[53] Financial Status - The company reported cash and investments of $3018 million as of December 31, 2025, with a cash runway anticipated through 2027[7, 61]